Clinical trials of first adult TB vaccine derived from human source begins

Tuberculosis, which is transmitted through the respiratory tract, kills more than 1.6 million people and infects more than 10 million worldwide each year.

By: Express News Service
Pune | Updated: March 29, 2024 05:29 AM IST

1 min read

Clinical trials of first adult TB vaccine derived from human source begins

Tuberculosis, which is transmitted through the respiratory tract, kills more than 1.6 million people and infects more than 10 million worldwide each year.

Bharat Biotech International Limited, in collaboration with Biofabri, has started a series of clinical trials in adults in the country to evaluate the safety, immunogenicity and efficacy of MTBVAC- the first vaccine against tuberculosis derived from a human source. According to a spokesperson at Bharat Biotech, this vaccine has been developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG vaccine for newborns, and to prevent TB disease in adults and adolescents, for whom there is currently no effective vaccine.

Tuberculosis, which is transmitted through the respiratory tract, kills more than 1.6 million people and infects more than 10 million worldwide each year.